Lifileucel (LN-44) achieved safety and efficacy irrespective of the number of aldesleukin (IL-2) doses administered to patients with advanced melanoma, according to data from a post-hoc analysis of the phase 2 C-144-01 trial (NCT02360579) presented at the 2022 ESMO Immuno-Oncology Annual Congress.
2022
‘I’m 28, I have melanoma and I don’t know how long I have to live’
Australian writer Natalie Fornasier has been battling an aggressive form of skin cancer for the past eight years and has just been told she only has a couple of months left to live.
Available Treatment Options Helps Decrease Melanoma Mortality Rate
New research suggests new pharmacological therapies are associated with a decrease in melanoma-related deaths.
Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma
Claire F. Verschraegen, MD, professor of Medicine, director of the Division of Medical Oncology, the Ohio State University College of Medicine, Diane Nye and Michael Rayden chair in Innovative Cancer Research, director for translational research, the Ohio State University Comprehensive Cancer Center (OSUCCC)– James, discusses the need to improve the management of treatment-related adverse effects (TRAEs) of immunotherapy in melanoma.